Further data from a previously-reported Phase 1/2 study of ProSavin, a gene therapy for patients with advanced Parkinson’s disease, confirms the treatment’s favourable safety profile. Developed by Oxford BioMedica Plc, ProSavin is delivered in a lentiviral vector.
